The use of fluconazole in neonatal intensive care units

Archives of Disease in Childhood

Volumn 94, Issue 12, 2009, Pages 983-987

  Manzoni, P ^a   Mostert, M ^b   Jacqz Aigrain, E ^c   Farina, D ^a  

^a S ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; CLARITHROMYCIN; FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLXANTHINE DERIVATIVE; NYSTATIN;

BLOODSTREAM INFECTION; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CANDIDIASIS; CHOLESTASIS; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEEDING BEHAVIOR; FUNGAL COLONIZATION; HIGH RISK INFANT; HUMAN; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS; NEWBORN INTENSIVE CARE; PERITONITIS; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEPSIS; URINARY TRACT INFECTION; VERY LOW BIRTH WEIGHT;

ANTIFUNGAL AGENTS; CANDIDIASIS; CROSS INFECTION; EVIDENCE-BASED MEDICINE; FLUCONAZOLE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; INTENSIVE CARE UNITS, NEONATAL; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 73249119073     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2008.154385     Document Type: Review

References (39)

1. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
2. Makhoul IR, Sujov P, Smolkin T, et al. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics 2002;109:34-9.
3. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006;117:1680-7.
4. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in verylow-birth-weight infants. Clin Microbiol Rev 2004;17:638-80.
5. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117:84-92.
6. Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birthweight infants with neonatal infection. JAMA 2004;292:2357-65.
7. Manzoni P, Maestri A, Leonessa M, et al. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J Perinatol 2006;26:23-30.
8. Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2007;(4):CD003850.
9. Kicklighter SD, Springer SC, Cox T, et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001;107:293-8.
10. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345:1660-6.
11. Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of ,1000 grams birth weight. J Pediatr 2005;147:172-9.
12. Bertini G, Perugi S, Dani C, et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr 2005;147:162-5.
13. Healy CM, Baker CJ, Zaccaria E, et al. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005;147:166-71.
14. Manzoni P, Arisio R, Mostert M, et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year retrospective cohort study. Pediatrics 2006;117:e22-32.
15. Uko S, Soghier LM, Vega M, et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics 2006;117:1243-52.
16. Aghai ZH, Mudduluru M, Nakhla TA, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol 2006;26:550-5.
17. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483-95.
18. Healy CM, Campbell JR, Zaccaria E, et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008;121:703-10.
19. Weitkamp JH, Ozdas A, LaFleur B, et al. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol 2008;28:405-11.
20. McCrossan BA, McHenry E, O'Neill F, et al. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed 2007;92:F454-8.
21. Kaufman DA, Manzoni P, Gurka MJ, Grossmann LB. Antifungal prophylaxis in the NICU. Curr Pediatr Rev 2007;3:277-88.
22. Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J 2008;27:731-7.
23. Kaufman DA, Chun-Soo K, Hazen KC, et al. Update on antifungal sensitivities of fungal isolates in high-risk preterm infants exposed to fluconazole prophylaxis (FP) in a neonatal intensive care unit over an 9-year period. Proceedings of the Pediatric Academic Societies Annual Conference; 2-5 May 2008, Honolulu, USA. Abstract 633758.10.
24. Burwell LA, Kaufman D, Blakely J, et al. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics 2006;118:e1019-26.
25. Bryant K, Maxfield C, Rabalais G. Renal candidiasis in neonates with candiduria. Pediatr Infect Dis J 1999;18:959-63.
26. Cotten CM, McDonald S, Stoll B, et al, National Institute for Child Health and Human Development Neonatal Research Network. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006;118:717-22.
27. Clerihew L, McGuire W. Antifungal prophylaxis for very low birthweight infants: UK national survey. Arch Dis Child Fetal Neonatal Ed 2008;93:F238-9.
28. Johnsson H, Ewald U. The rate of candidaemia in preterm infants born at a gestational age of 23-28 weeks is inversely correlated to gestational age. Acta Paediatr 2004;93:954-8.
29. Coates EW, Karlowicz MG, Croitoru DP, et al. Distinctive distribution of pathogens associated with peritonitis in neonates with focal intestinal perforation compared with necrotizing enterocolitis. Pediatrics 2005;116:e241-6.
30. Feja KN, Wu F, Roberts K, et al. Risk factors for candidaemia in critically ill infants: a matched case-control study. J Pediatr 2005;147:156-61.
31. Baley JE, Kliegman RM, Boxerbaum B, et al. Fungal colonization in the very low birth weight infant. Pediatrics 1986;78:225-32.
32. Manzoni P, Farina D, Leonessa ML, et al. Risk Factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics 2006;118:2359-64.
33. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002;50:56-65.
34. Sarvikivi E, Lyytikainen O, Soll DR, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005;43:2729-35.
35. Blot S, Janssens R, Claeys G, et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006;58:474-7.
36. Marr KA, Seidel K, White TC, et al. Candidaemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16.
37. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
38. Karlowicz MG, Hashimoto LN, Kelly RE Jr, et al. Should central venous catheters be removed as soon as candidaemia is detected in neonates? Pediatrics 2000;106:E63.
39. Pappas PG, Rex JH, Sobel JD, et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.